Results 201 to 210 of about 34,967 (216)

Rivaroxaban: A New Oral Factor Xa Inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
Dagmar Kubitza, Volker Laux, Elisabeth Perzborn   +2 more
exaly  

Rivaroxaban

Clinical Pharmacokinetics, 2012
Paolo Prandoni, Giancarlo Agnelli, Frank Misselwitz   +2 more
exaly  

Pharmacodynamic and pharmacokinetic basics of rivaroxaban

Fundamental and Clinical Pharmacology, 2012
Reinhold Kreutz
exaly  

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial

Stroke, 2014
Keith Fox, Abraham Oomman, Ka Sing Lawrence Wong   +2 more
exaly  

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation

Stroke, 2017
Alena Shantsila, Ying Bai
exaly  

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial

Journal of the American Heart Association, 2014
Manesh Patel, Graeme Hankey, Scott Berkowitz   +2 more
exaly  

Cerebral hemorrhage under rivaroxaban

International Journal of Cardiology, 2013

exaly  

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

Thrombosis and Haemostasis, 2012
Gilles Pernod, Raphaël Marlu
exaly  

Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)

Journal of Cardiology, 2018
Yutaka Nakaya, Masahiko Fukatani
exaly  

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

British Journal of Clinical Pharmacology, 2010
exaly